157 related articles for article (PubMed ID: 31074291)
1. Ocular manifestations of intermediate cystinosis: To treat or not to treat?
Sousa-Neves F; Ribeiro AC; Saraiva E; Ribeiro L; Sequeira J; Varandas R
Eur J Ophthalmol; 2020 Nov; 30(6):NP7-NP10. PubMed ID: 31074291
[TBL] [Abstract][Full Text] [Related]
2.
Ozdemir HB; Özmen MC; Aktas Z; Hasanreisoglu M
Indian J Ophthalmol; 2019 Jan; 67(1):153-155. PubMed ID: 30574930
[TBL] [Abstract][Full Text] [Related]
3. [Ocular treatment of cystinosis with eye drop containing cysteamine].
Csorba A; Maka E; Szabó A; Kelen K; Reusz G; Nagy ZZ
Orv Hetil; 2022 May; 163(21):846-852. PubMed ID: 35598215
[TBL] [Abstract][Full Text] [Related]
4. Evolution of ocular manifestations in nephropathic cystinosis: a long-term study of a population treated with cysteamine.
Dureau P; Broyer M; Dufier JL
J Pediatr Ophthalmol Strabismus; 2003; 40(3):142-6. PubMed ID: 12795432
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of topical cysteamine in nephropathic cystinosis.
Al-Hemidan A; Shoughy SS; Kozak I; Tabbara KF
Br J Ophthalmol; 2017 Sep; 101(9):1234-1237. PubMed ID: 28057644
[TBL] [Abstract][Full Text] [Related]
6. In vivo confocal microscopy and anterior segment optical coherence tomography analysis of the cornea in nephropathic cystinosis.
Labbé A; Niaudet P; Loirat C; Charbit M; Guest G; Baudouin C
Ophthalmology; 2009 May; 116(5):870-6. PubMed ID: 19410944
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of treatment with cysteamine eyedrops for cystinosis with confocal microscopy.
Tavares R; Coelho D; Macário MC; Torres A; Quadrado MJ; Murta J
Cornea; 2009 Sep; 28(8):938-40. PubMed ID: 19654516
[TBL] [Abstract][Full Text] [Related]
8. A New Viscous Cysteamine Eye Drops Treatment for Ophthalmic Cystinosis: An Open-Label Randomized Comparative Phase III Pivotal Study.
Liang H; Labbé A; Le Mouhaër J; Plisson C; Baudouin C
Invest Ophthalmol Vis Sci; 2017 Apr; 58(4):2275-2283. PubMed ID: 28426870
[TBL] [Abstract][Full Text] [Related]
9. Photophobia and corneal crystal density in nephropathic cystinosis: an in vivo confocal microscopy and anterior-segment optical coherence tomography study.
Liang H; Baudouin C; Tahiri Joutei Hassani R; Brignole-Baudouin F; Labbe A
Invest Ophthalmol Vis Sci; 2015 May; 56(5):3218-25. PubMed ID: 26024106
[TBL] [Abstract][Full Text] [Related]
10. Ocular cystinosis: Rarity redefined.
Naik MP; Sethi HS; Dabas S
Indian J Ophthalmol; 2019 Jul; 67(7):1158-1159. PubMed ID: 31238435
[No Abstract] [Full Text] [Related]
11. Clinicopathological features of ocular cystinosis.
Kocabora MS; Ozbilen KT; Altunsoy M; Ahishali B; Taskapili M
Clin Exp Ophthalmol; 2008 Nov; 36(8):778-81. PubMed ID: 19128385
[TBL] [Abstract][Full Text] [Related]
12. A randomized clinical trial of topical cysteamine disulfide (cystamine) versus free thiol (cysteamine) in the treatment of corneal cystine crystals in cystinosis.
Iwata F; Kuehl EM; Reed GF; McCain LM; Gahl WA; Kaiser-Kupfer MI
Mol Genet Metab; 1998 Aug; 64(4):237-42. PubMed ID: 9758713
[TBL] [Abstract][Full Text] [Related]
13. Establishing an objective biomarker for corneal cystinosis using a threshold-based Spectral domain optical coherence tomography imaging algorithm.
Keidel L; Elhardt C; Hohenfellner K; Priglinger S; Schworm B; Wertheimer C; Priglinger C; Luft N
Acta Ophthalmol; 2021 Mar; 99(2):e189-e195. PubMed ID: 32833325
[TBL] [Abstract][Full Text] [Related]
14. Examination of corneal deposits in nephropathic cystinosis using in vivo confocal microscopy and anterior segment optical coherence tomography: an age-dependent cross sectional study.
Csorba A; Maka E; Maneschg OA; Szabó A; Szentmáry N; Csidey M; Resch M; Imre L; Knézy K; Nagy ZZ
BMC Ophthalmol; 2020 Feb; 20(1):73. PubMed ID: 32102651
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Scheimpflug Corneal Tomography and Anterior Segment Optical Coherence Tomography Measurements in Corneal Cystinosis: A Case Series.
Vercauteren L; Consejo A; De Vries MJ; Krolo I; Koppen C; Ní Dhubhghaill S
Eye Contact Lens; 2024 Jul; 50(7):321-328. PubMed ID: 38630953
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of topical cysteamine therapy in the CTNS(-/-) knockout mouse using in vivo confocal microscopy.
Simpson JL; Nien CJ; Flynn KJ; Jester JV
Mol Vis; 2011; 17():2649-54. PubMed ID: 22065917
[TBL] [Abstract][Full Text] [Related]
17. Cysteamin eyedrops in three patients with nephropathic cystinosis.
Blanksma LJ; Jansonius NM; Reitsma-Bierens WC
Doc Ophthalmol; 1996-1997; 92(1):51-3. PubMed ID: 9181332
[No Abstract] [Full Text] [Related]
18. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.
Gahl WA; Kuehl EM; Iwata F; Lindblad A; Kaiser-Kupfer MI
Mol Genet Metab; 2000; 71(1-2):100-20. PubMed ID: 11001803
[TBL] [Abstract][Full Text] [Related]
19. The effect of topical cysteamine drops on reducing crystal formation within the cornea of patients affected by nephropathic cystinosis.
MacDonald IM; Noel LP; Mintsioulis G; Clarke WN
J Pediatr Ophthalmol Strabismus; 1990; 27(5):272-4. PubMed ID: 2246744
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of cystinosis patients treated with 0.55% cysteamine hydrochloride.
Liang H; Labbé A; Baudouin C; Plisson C; Giordano V
Br J Ophthalmol; 2021 May; 105(5):608-613. PubMed ID: 32593979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
